INO
Income statement / Annual
Last year (2023), Inovio Pharmaceuticals, Inc.'s total revenue was $832,010.00,
a decrease of 91.89% from the previous year.
In 2023, Inovio Pharmaceuticals, Inc.'s net income was -$135.12 M.
See Inovio Pharmaceuticals, Inc.’s key income statements, including revenue, expenses, profit, and income.
| Period |
FY-2023
|
FY-2022
|
FY-2021
|
FY-2020
|
FY-2019
|
FY-2018
|
FY-2017
|
FY-2016
|
FY-2015
|
FY-2014
|
| Period Ended |
12/31/2023 |
12/31/2022 |
12/31/2021 |
12/31/2020 |
12/31/2019 |
12/31/2018 |
12/31/2017 |
12/31/2016 |
12/31/2015 |
12/31/2014 |
| Operating Revenue |
$832,010.00
|
$10.26 M
|
$1.77 M
|
$7.41 M
|
$4.11 M
|
$30.48 M
|
$42.22 M
|
$35.37 M
|
$40.57 M
|
$10.46 M
|
| Cost of Revenue |
$3.50 M |
$5.50 M |
$4.73 M |
$94.25 M |
$88.02 M |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
| Gross Profit |
-$2.67 M |
$4.77 M |
-$2.96 M |
-$86.83 M |
-$83.91 M |
$30.48 M |
$42.22 M |
$35.37 M |
$40.57 M |
$10.46 M |
| Gross Profit Ratio |
-3.21 |
0.46 |
-1.67 |
-11.72 |
-20.41 |
1 |
1 |
1 |
1 |
1 |
| Research and Development
Expenses |
$88.48 M
|
$187.65 M
|
$249.24 M
|
$94.25 M
|
$88.02 M
|
$95.26 M
|
$98.57 M
|
$88.71 M
|
$57.79 M
|
$34.10 M
|
| General & Administrative
Expenses |
$47.58 M
|
$90.19 M
|
$53.75 M
|
$37.25 M
|
$27.20 M
|
$29.32 M
|
$28.29 M
|
$23.89 M
|
$18.06 M
|
$15.86 M
|
| Selling & Marketing
Expenses |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Selling, General &
Administrative Expenses |
$47.58 M
|
$90.19 M
|
$53.75 M
|
$37.25 M
|
$27.20 M
|
$29.32 M
|
$28.29 M
|
$23.89 M
|
$18.06 M
|
$15.86 M
|
| Other Expenses |
-$3.50 M |
-$3.86 M |
$343,371.00 |
$3.42 M |
$496,200.00 |
$360,795.00 |
$806,819.00 |
$127,554.00 |
$177,561.00 |
$348,143.00 |
| Operating Expenses |
$132.56 M |
$277.84 M |
$302.99 M |
$131.49 M |
$115.22 M |
$124.57 M |
$126.86 M |
$112.60 M |
$75.86 M |
$49.95 M |
| Cost And Expenses |
$136.06 M |
$277.84 M |
$302.99 M |
$131.49 M |
$115.22 M |
$124.57 M |
$126.86 M |
$112.60 M |
$75.86 M |
$49.95 M |
| Interest Income |
$8.13 M |
$4.78 M |
$3.36 M |
$3.31 M |
$2.61 M |
$2.26 M |
$1.61 M |
$1.40 M |
$305,071.00 |
$0.00 |
| Interest Expense |
$1.22 M |
$1.25 M |
$1.94 M |
$8.70 M |
$7.95 M |
$346,086.00 |
$4.56 M |
$139,249.00 |
$0.00 |
$0.00 |
| Depreciation &
Amortization |
$3.50 M
|
$5.50 M
|
$4.73 M
|
$4.63 M
|
$5.52 M
|
$5.00 M
|
$3.47 M
|
$3.09 M
|
$1.92 M
|
$1.57 M
|
| EBITDA |
-$130.39 M
|
-$270.90 M
|
-$296.56 M
|
-$149.56 M
|
-$107.34 M
|
-$89.80 M
|
-$84.74 M
|
-$74.15 M
|
-$33.37 M
|
-$37.93 M
|
| EBITDA Ratio |
-156.72 |
-26.17 |
-165.28 |
-10.28 |
-25.68 |
-2.93 |
-1.97 |
-2.13 |
-0.85 |
-3.66 |
| Operating Income Ratio
|
-162.53
|
-26.07
|
-169.72
|
-16.74
|
-27.02
|
-3.09
|
-1.98
|
-2.16
|
-0.85
|
-3.78
|
| Total Other
Income/Expenses Net |
$109,305.00
|
-$10.08 M
|
-$2.01 M
|
-$38.81 M
|
-$9.70 M
|
-$706,881.00
|
-$4.56 M
|
$2.50 M
|
$3.08 M
|
$3.36 M
|
| Income Before Tax |
-$135.12 M |
-$277.65 M |
-$303.22 M |
-$162.89 M |
-$120.81 M |
-$94.80 M |
-$88.21 M |
-$73.74 M |
-$31.20 M |
-$36.14 M |
| Income Before Tax Ratio
|
-162.4
|
-27.06
|
-170.85
|
-21.98
|
-29.38
|
-3.11
|
-2.09
|
-2.08
|
-0.77
|
-3.46
|
| Income Tax Expense |
$0.00 |
$10.01 M |
$2.16 M |
$52.20 M |
-$257,335.00 |
$2.17 M |
$1.76 M |
-$4.62 M |
-$2.10 M |
-$3.72 M |
| Net Income |
-$135.12 M |
-$287.66 M |
-$305.38 M |
-$215.09 M |
-$120.55 M |
-$96.97 M |
-$88.21 M |
-$73.74 M |
-$29.19 M |
-$36.12 M |
| Net Income Ratio |
-162.4 |
-28.03 |
-172.07 |
-29.02 |
-29.32 |
-3.18 |
-2.09 |
-2.08 |
-0.72 |
-3.45 |
| EPS |
-6.09 |
-14.47 |
-17.55 |
-16.64 |
-14.65 |
-1.05 |
-1.08 |
-1.01 |
-0.43 |
-0.61 |
| EPS Diluted |
-6.09 |
-14.47 |
-17.55 |
-16.64 |
-14.65 |
-1.05 |
-1.08 |
-1.01 |
-0.43 |
-0.61 |
| Weighted Average Shares
Out |
$22.17 M
|
$19.89 M
|
$17.40 M
|
$12.93 M
|
$8.23 M
|
$92.35 M
|
$81.78 M
|
$73.01 M
|
$68.20 M
|
$59.13 M
|
| Weighted Average Shares
Out Diluted |
$22.17 M
|
$19.89 M
|
$17.40 M
|
$12.93 M
|
$8.23 M
|
$92.54 M
|
$81.92 M
|
$73.21 M
|
$68.37 M
|
$59.41 M
|
| Link |
|
|
|
|
|
|
|
|
|
|
